10x Genomics (TXG) Is Up 19.8% After Pan-Cancer Atlas Collaboration With Garvan and University of Tokyo

• On November 18, 2025, the Garvan Institute of Medical Research and the University of Tokyo announced the Asia-Pacific Spatial Translational Research Alliance (ASTRA), a major initiative to create a comprehensive pan-cancer spatial atlas using 10x Genomics’ Xenium platform across 2,000 tumor samples.
• This collaboration aims to establish new hubs and digital infrastructure for sharing spatial and molecular cancer data, particularly serving underrepresented populations across the Asia-Pacific region.
• We’ll explore how ASTRA’s adoption of the Xenium platform could influence 10x Genomics’ global partnerships and opportunities in precision oncology.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

10x Genomics Investment Narrative Recap

To believe in 10x Genomics as a shareholder is to have confidence in global adoption of advanced spatial genomics tools and the growth of precision oncology. The new ASTRA initiative enhances global visibility for the Xenium platform, but given persistent macroeconomic uncertainty and constrained research budgets, particularly in the US and Europe, its effect on near-term revenue catalysts or risk profile is not material right now.

The October 2025 launch of the next-generation Flex assay for scalable single-cell analysis is especially relevant, signaling the company’s focus on expanding product breadth and throughput. This aligns closely with the clinical and academic demands highlighted by the ASTRA project and supports 10x’s efforts to capture recurring consumables revenue through flexibility and scale. However, investors should also consider the potential for price competition and margin pressure as product transitions accelerate.

In contrast, a key ongoing concern that investors should be aware of is the company’s exposure to intense price sensitivity in end markets, especially if...

Read the full narrative on 10x Genomics (it's free!)

10x Genomics' narrative projects $688.4 million in revenue and $97.8 million in earnings by 2028. This requires 2.2% yearly revenue growth and a $182.4 million increase in earnings from -$84.6 million.

Uncover how 10x Genomics' forecasts yield a $16.36 fair value, a 13% downside to its current price.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community place 10x Genomics’ price between US$6.47 and US$23.59 per share. With persistent funding pressures and evolving product pricing, the potential impact on revenue and earnings recovery continues to shape wider market opinions, see what other investors are thinking.

Explore 6 other fair value estimates on 10x Genomics - why the stock might be worth as much as 26% more than the current price!

Build Your Own 10x Genomics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Outshine the giants: these 25 early-stage AI stocks could fund your retirement.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com